Evidence map›Paper›PMID 41843069›Full record

ArticleVirchows Archiv : an international journal of pathology2026

T-prolymphocytic leukemia with three distinct immunophenotypic subsets.

Nana P Matsumoto, Katelynn E Davis, Nidhi Aggarwal, Sara A Monaghan, Ahmad Al-Attar

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nana P MatsumotoDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA. matsumoton@upmc.edu.ORCID http://orcid.org/0000-0002-2622-9829
Katelynn E DavisDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA.ORCID http://orcid.org/0000-0003-3554-0288
Nidhi AggarwalDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA.ORCID http://orcid.org/0000-0003-0277-0132
Sara A MonaghanDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA.ORCID http://orcid.org/0000-0001-5638-999X
Ahmad Al-AttarDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA.ORCID http://orcid.org/0000-0002-0707-1886

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T-prolymphocytic leukemia (T-PLL) is a rare, aggressive mature T-cell neoplasm usually affecting older adults, often presenting with marked leukocytosis and splenomegaly. It is characteristically associated with recurrent chromosome 14 rearrangements that drive overexpression of TCL1 family oncogenes. Neoplastic cells generally show a mature T-cell immunophenotype with preserved pan-T cell markers, most commonly CD4⁺ with or without CD8 expression. Although T-PLL can harbor substantial genetic complexity that may lead to subclonal evolution, overt phenotypic diversification into distinctly separable abnormal T-cell populations within a single case of T-PLL is rarely documented, particularly among those characterized by multiparametric flow cytometry. This brief report describes a patient with T-PLL in whom three distinct abnormal T-cell subsets were delineated by flow cytometric analysis using TRBC1. This case illustrates striking intratumoral heterogeneity in a neoplasm that is typically regarded as phenotypically uniform and demonstrates the utility of TRBC1 analysis in refining diagnostic assessment.

Indexed as

Flow cytometryT-prolymphocytic leukemiaTRBC1

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.